BioCentury | Feb 16, 2017
Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
BioCentury | Jan 19, 2017
Finance

Kurma chameleon

...to develop a new class of immunosuppressive drugs, based on research from Alain Fischer at Hopital Necker-Enfants Malades...
...for Biotechnology (VIB), Ghent, Belgium Gadeta B.V., Utrecht, the Netherlands GammaDelta Therapeutics Ltd., London, U.K. Hopital Necker-Enfants Malades...
BioCentury | Jul 20, 2015
Strategy

Window to gene therapy

Biogen Inc .'s recent deal with Applied Genetic Technologies Corp. is mainly a play to gain hands-on experience developing and manufacturing gene therapies while building its own gene therapy research unit. Early last year, after...
BioCentury | Oct 13, 2014
Clinical News

Gamma-retrovirus gene therapy: Phase I/II data

...Hospital for Children NHS Foundation Trust and Assistance Publique - Hopitaux de Paris , respectively. Hopital Necker-Enfants Malades...
BioCentury | Oct 29, 2012
Emerging Company Profile

PathoQuest: Positive identification

...Clinical status: Pilot Founded: 2010 as a spinout of Institut Pasteur University collaborators: Institut Pasteur, Hopital Necker...
BioCentury | Aug 9, 2010
Clinical News

Gamma-c gene therapy hematology data

...2003). An FDA advisory committee advised the agency to remove the clinical hold in 2003. Hopital Necker-Enfants Malades...
BioCentury | Jan 22, 2007
Tools & Techniques

Industrializing DNA modification

...orphan genetic disorders, on which it is working with "motivated" academics. These include work with Hopital Necker-Enfants Malades...
BioCentury | May 1, 2006
Tools & Techniques

Detective work

...that result in reduced proliferation and survival of immune cells. In an academic trial at Hopital Necker-Enfants Malades...
BioCentury | Oct 20, 2003
Clinical News

Gamma-c gene therapy hematology data

...vector integration in proximity to the LMO2 proto-oncogene promoter, leading to aberrant expression of LMO2. Hopital Necker-Enfants Malades...
BioCentury | Oct 10, 2002
Politics & Policy

FDA panel recommends lifting SCID holds

...deficiency disease (SCID). The U.S. trial holds followed news that a gene therapy trial at Hopital Necker-Enfants Malades...
Items per page:
1 - 10 of 17
BioCentury | Feb 16, 2017
Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
BioCentury | Jan 19, 2017
Finance

Kurma chameleon

...to develop a new class of immunosuppressive drugs, based on research from Alain Fischer at Hopital Necker-Enfants Malades...
...for Biotechnology (VIB), Ghent, Belgium Gadeta B.V., Utrecht, the Netherlands GammaDelta Therapeutics Ltd., London, U.K. Hopital Necker-Enfants Malades...
BioCentury | Jul 20, 2015
Strategy

Window to gene therapy

Biogen Inc .'s recent deal with Applied Genetic Technologies Corp. is mainly a play to gain hands-on experience developing and manufacturing gene therapies while building its own gene therapy research unit. Early last year, after...
BioCentury | Oct 13, 2014
Clinical News

Gamma-retrovirus gene therapy: Phase I/II data

...Hospital for Children NHS Foundation Trust and Assistance Publique - Hopitaux de Paris , respectively. Hopital Necker-Enfants Malades...
BioCentury | Oct 29, 2012
Emerging Company Profile

PathoQuest: Positive identification

...Clinical status: Pilot Founded: 2010 as a spinout of Institut Pasteur University collaborators: Institut Pasteur, Hopital Necker...
BioCentury | Aug 9, 2010
Clinical News

Gamma-c gene therapy hematology data

...2003). An FDA advisory committee advised the agency to remove the clinical hold in 2003. Hopital Necker-Enfants Malades...
BioCentury | Jan 22, 2007
Tools & Techniques

Industrializing DNA modification

...orphan genetic disorders, on which it is working with "motivated" academics. These include work with Hopital Necker-Enfants Malades...
BioCentury | May 1, 2006
Tools & Techniques

Detective work

...that result in reduced proliferation and survival of immune cells. In an academic trial at Hopital Necker-Enfants Malades...
BioCentury | Oct 20, 2003
Clinical News

Gamma-c gene therapy hematology data

...vector integration in proximity to the LMO2 proto-oncogene promoter, leading to aberrant expression of LMO2. Hopital Necker-Enfants Malades...
BioCentury | Oct 10, 2002
Politics & Policy

FDA panel recommends lifting SCID holds

...deficiency disease (SCID). The U.S. trial holds followed news that a gene therapy trial at Hopital Necker-Enfants Malades...
Items per page:
1 - 10 of 17